<p>REGENXBIO Inc. (NASDAQ:RGNX - 獲取免費報告) 的股價在週二上漲了 10.7%，因為華爾街 Zen 將該股票的評級從賣出上調至持有。該公司股價最高達到$13.59，最後交易價為$13.54。在交易過程中，約有 409,030 股易手，較 847,395 股的日均交易量下降了 52%。該股票之前的收盤價為$12.23。</p>
<p>其他一些股票研究分析師也對 RGNX 發表了看法。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 REGENXBIO 股票的 “賣出（d-）” 評級。加拿大皇家銀行在 11 月 7 日的報告中將 REGENXBIO 的目標價從$17.00 上調至$19.00，並給予該公司 “跑贏大盤” 的評級。HC Wainwright 在 10 月 7 日的報告中重新發布了 “買入” 評級，並設定了$34.00 的目標價。巴克萊在 8 月 8 日的研究報告中將 REGENXBIO 的目標價從$50.00 下調至$37.00，並對該公司設定了 “增持” 評級。最後，Chardan Capital 在 11 月 20 日的研究報告中重申了 “買入” 評級，並設定了$52.00 的目標價。五位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為$28.63。</p>
<p><strong>獲取我們關於 RGNX 的最新研究報告</strong></p>
<h2>REGENXBIO 的內部活動</h2>
<p>在相關消息中，首席執行官 Curran Simpson 在 10 月 9 日的交易中出售了 20,811 股公司的股票。該股票以平均價格$12.62 出售，總交易額為$262,634.82。交易完成後，首席執行官持有 216,162 股公司股票，價值$2,727,964.44。這筆交易代表了他們持股比例的 8.78% 的減少。該出售在向 SEC 的文件中披露，相關文件可通過 SEC 網站獲取。在過去 90 天內，內部人士已出售價值$416,598 的 36,169 股公司股票。目前，內部人士持有該股票的 12.79%。</p>
<h2>機構資金流入和流出</h2>
<p>對沖基金最近增加或減少了對該公司的持股。摩根大通在第三季度將其在 REGENXBIO 的持股提高了 4.8%。摩根大通目前持有 4,037,248 股該生物技術公司的股票，價值$38,959,000，在上個季度又購買了 185,223 股。先鋒集團在第一季度將其在 REGENXBIO 的持股提高了 16.3%。先鋒集團目前持有 3,472,988 股該生物技術公司的股票，價值$24,832,000，在此期間又購買了 487,036 股。Geode Capital Management 在第二季度將其在 REGENXBIO 的持股提高了 1.9%。Geode Capital Management 目前持有 1,128,521 股該生物技術公司的股票，價值$9,267,000，在上個季度又收購了 21,575 股。Integral Health Asset Management 在第三季度將其在 REGENXBIO 的持股提高了 57.1%。Integral Health Asset Management 目前持有 1,100,000 股該生物技術公司的股票，價值$10,615,000，在此期間又收購了 400,000 股。最後，AQR Capital Management 在第二季度將其在 REGENXBIO 的持股提高了 49.9%。AQR Capital Management 目前持有 930,196 股該生物技術公司的股票，價值$7,637,000，在上個季度又收購了 309,601 股。機構投資者和對沖基金持有該公司 88.08% 的股票。</p>
<h2>REGENXBIO 上漲 9.8%</h2>
<p>該公司的 50 日移動平均線為$11.21，200 日移動平均線為$9.69。該公司的市值為$679.83 百萬，市盈率為-3.87，貝塔值為 1.22。</p>
<p>REGENXBIO (NASDAQ:RGNX - 獲取免費報告) 最近在 11 月 6 日發佈了其財報。這家生物技術公司報告本季度每股收益為 ($1.20)，超出分析師共識預期的 ($1.38) $0.18。該公司本季度的收入為$29.73 百萬，而共識預期為$24.41 百萬。REGENXBIO 的股本回報率為-78.29%，淨利潤率為-110.29%。平均而言，研究分析師預測 REGENXBIO Inc.在當前財政年度將發佈-4.84 的每股收益。</p>
<h2>REGENXBIO 公司簡介</h2>
<p>(獲取免費報告)</p>
<p>REGENXBIO Inc 是一家臨牀階段的生物技術公司，提供基因療法，將功能基因傳遞給美國的遺傳缺陷細胞。其基因療法產品候選者基於 NAV 技術平台，這是一種專有的腺病毒相關病毒基因傳遞平台。該公司的產品管線包括用於治療濕性年齡相關性黃斑變性、糖尿病視網膜病變和其他慢性視網膜疾病的 ABBV-RGX-314，以及正在進行 I/II 期臨牀試驗的 RGX-202，用於治療杜氏肌營養不良症。</p>
<h2>精選文章</h2>
<ul>
<li>我們更喜歡的五隻股票超過 REGENXBIO</li>
<li>投資旅遊股票的好處</li>
<li>錯過了人工智能的繁榮？這兩隻被壓制的股票可能是你的第二次機會</li>
<li>消費者價格指數測量什麼？</li>
<li>六旗的新領導者：過山車結束了嗎？</li>
<li>股票交易術語 - 每個投資者需要了解的股票術語</li>
<li>百度可能成為全球人工智能的黑馬的三個理由</li>
</ul>
<p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
<h2>你現在應該投資$1,000 在 REGENXBIO 嗎？</h2>
<p>在你考慮 REGENXBIO 之前，你需要聽聽這個。</p>
<p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 REGENXBIO 並不在名單上。</p>
<p>雖然 REGENXBIO 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
<p>在這裏查看這五隻股票</p>

RGNX

<p>REGENXBIO 的股票在華爾街 Zen 將其評級從賣出上調至持有後上漲了 10.7%。該股票交易價格為 13.54 美元，交易量顯著減少。分析師的評級各不相同，普遍共識為 “適度買入”，目標價格為 28.63 美元。還注意到內部交易和機構投資，摩根大通、先鋒集團等持有大量股份。該公司報告的收益好於預期，但股本回報率為負，淨利潤率也不理想</p>

<p>REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report)'s share price was up 10.7% on Tuesday after Wall Street Zen upgraded the stock from a sell rating to a hold rating. The company traded as high as $13.59 and last traded at $13.54. Approximately 409,030 shares changed hands during trading, a decline of 52% from the average daily volume of 847,395 shares. The stock had previously closed at $12.23.</p>
<div class="lb-trans"><p>REGENXBIO Inc. (NASDAQ:RGNX - 獲取免費報告) 的股價在週二上漲了 10.7%，因為華爾街 Zen 將該股票的評級從賣出上調至持有。該公司股價最高達到$13.59，最後交易價為$13.54。在交易過程中，約有 409,030 股易手，較 847,395 股的日均交易量下降了 52%。該股票之前的收盤價為$12.23。</p>
</div><p>A number of other equities research analysts have also weighed in on RGNX. Weiss Ratings restated a &#34;sell (d-)&#34; rating on shares of REGENXBIO in a research note on Wednesday, October 8th. Royal Bank Of Canada upped their price target on shares of REGENXBIO from $17.00 to $19.00 and gave the company an &#34;outperform&#34; rating in a report on Friday, November 7th. HC Wainwright reissued a &#34;buy&#34; rating and set a $34.00 price objective on shares of REGENXBIO in a report on Tuesday, October 7th. Barclays dropped their target price on shares of REGENXBIO from $50.00 to $37.00 and set an &#34;overweight&#34; rating for the company in a research report on Friday, August 8th. Finally, Chardan Capital reaffirmed a &#34;buy&#34; rating and set a $52.00 price target on shares of REGENXBIO in a research report on Thursday, November 20th. Five investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of &#34;Moderate Buy&#34; and a consensus target price of $28.63.</p>
<div class="lb-trans"><p>其他一些股票研究分析師也對 RGNX 發表了看法。Weiss Ratings 在 10 月 8 日的研究報告中重申了對 REGENXBIO 股票的 “賣出（d-）” 評級。加拿大皇家銀行在 11 月 7 日的報告中將 REGENXBIO 的目標價從$17.00 上調至$19.00，並給予該公司 “跑贏大盤” 的評級。HC Wainwright 在 10 月 7 日的報告中重新發布了 “買入” 評級，並設定了$34.00 的目標價。巴克萊在 8 月 8 日的研究報告中將 REGENXBIO 的目標價從$50.00 下調至$37.00，並對該公司設定了 “增持” 評級。最後，Chardan Capital 在 11 月 20 日的研究報告中重申了 “買入” 評級，並設定了$52.00 的目標價。五位投資分析師對該股票給予了買入評級，一位給予了持有評級，一位給予了賣出評級。根據 MarketBeat.com 的數據，該公司目前的共識評級為 “適度買入”，共識目標價為$28.63。</p>
</div><p><strong>Get Our Latest Research Report on RGNX</strong></p>
<div class="lb-trans"><p><strong>獲取我們關於 RGNX 的最新研究報告</strong></p>
</div><h2>Insider Activity at REGENXBIO</h2>
<div class="lb-trans"><h2>REGENXBIO 的內部活動</h2>
</div><p>In related news, CEO Curran Simpson sold 20,811 shares of the firm's stock in a transaction dated Thursday, October 9th. The stock was sold at an average price of $12.62, for a total transaction of $262,634.82. Following the completion of the transaction, the chief executive officer owned 216,162 shares of the company's stock, valued at $2,727,964.44. This trade represents a 8.78% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 36,169 shares of company stock worth $416,598. 12.79% of the stock is currently owned by insiders.</p>
<div class="lb-trans"><p>在相關消息中，首席執行官 Curran Simpson 在 10 月 9 日的交易中出售了 20,811 股公司的股票。該股票以平均價格$12.62 出售，總交易額為$262,634.82。交易完成後，首席執行官持有 216,162 股公司股票，價值$2,727,964.44。這筆交易代表了他們持股比例的 8.78% 的減少。該出售在向 SEC 的文件中披露，相關文件可通過 SEC 網站獲取。在過去 90 天內，內部人士已出售價值$416,598 的 36,169 股公司股票。目前，內部人士持有該股票的 12.79%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>機構資金流入和流出</h2>
</div><p>Hedge funds have recently added to or reduced their stakes in the business. JPMorgan Chase &amp; Co. lifted its holdings in shares of REGENXBIO by 4.8% during the third quarter. JPMorgan Chase &amp; Co. now owns 4,037,248 shares of the biotechnology company's stock valued at $38,959,000 after purchasing an additional 185,223 shares during the last quarter. Vanguard Group Inc. boosted its holdings in shares of REGENXBIO by 16.3% in the first quarter. Vanguard Group Inc. now owns 3,472,988 shares of the biotechnology company's stock worth $24,832,000 after buying an additional 487,036 shares during the period. Geode Capital Management LLC increased its position in shares of REGENXBIO by 1.9% in the second quarter. Geode Capital Management LLC now owns 1,128,521 shares of the biotechnology company's stock worth $9,267,000 after acquiring an additional 21,575 shares in the last quarter. Integral Health Asset Management LLC raised its holdings in shares of REGENXBIO by 57.1% during the third quarter. Integral Health Asset Management LLC now owns 1,100,000 shares of the biotechnology company's stock valued at $10,615,000 after acquiring an additional 400,000 shares during the period. Finally, AQR Capital Management LLC lifted its position in shares of REGENXBIO by 49.9% in the 2nd quarter. AQR Capital Management LLC now owns 930,196 shares of the biotechnology company's stock valued at $7,637,000 after acquiring an additional 309,601 shares in the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.</p>
<div class="lb-trans"><p>對沖基金最近增加或減少了對該公司的持股。摩根大通在第三季度將其在 REGENXBIO 的持股提高了 4.8%。摩根大通目前持有 4,037,248 股該生物技術公司的股票，價值$38,959,000，在上個季度又購買了 185,223 股。先鋒集團在第一季度將其在 REGENXBIO 的持股提高了 16.3%。先鋒集團目前持有 3,472,988 股該生物技術公司的股票，價值$24,832,000，在此期間又購買了 487,036 股。Geode Capital Management 在第二季度將其在 REGENXBIO 的持股提高了 1.9%。Geode Capital Management 目前持有 1,128,521 股該生物技術公司的股票，價值$9,267,000，在上個季度又收購了 21,575 股。Integral Health Asset Management 在第三季度將其在 REGENXBIO 的持股提高了 57.1%。Integral Health Asset Management 目前持有 1,100,000 股該生物技術公司的股票，價值$10,615,000，在此期間又收購了 400,000 股。最後，AQR Capital Management 在第二季度將其在 REGENXBIO 的持股提高了 49.9%。AQR Capital Management 目前持有 930,196 股該生物技術公司的股票，價值$7,637,000，在上個季度又收購了 309,601 股。機構投資者和對沖基金持有該公司 88.08% 的股票。</p>
</div><h2>REGENXBIO Trading Up 9.8%</h2>
<div class="lb-trans"><h2>REGENXBIO 上漲 9.8%</h2>
</div><p>The company's 50-day moving average is $11.21 and its 200 day moving average is $9.69. The firm has a market cap of $679.83 million, a PE ratio of -3.87 and a beta of 1.22.</p>
<div class="lb-trans"><p>該公司的 50 日移動平均線為$11.21，200 日移動平均線為$9.69。該公司的市值為$679.83 百萬，市盈率為-3.87，貝塔值為 1.22。</p>
</div><p>REGENXBIO (NASDAQ:RGNX - Get Free Report) last issued its earnings results on Thursday, November 6th. The biotechnology company reported ($1.20) earnings per share for the quarter, beating analysts' consensus estimates of ($1.38) by $0.18. The company had revenue of $29.73 million for the quarter, compared to the consensus estimate of $24.41 million. REGENXBIO had a negative return on equity of 78.29% and a negative net margin of 110.29%. On average, research analysts predict that REGENXBIO Inc. will post -4.84 EPS for the current fiscal year.</p>
<div class="lb-trans"><p>REGENXBIO (NASDAQ:RGNX - 獲取免費報告) 最近在 11 月 6 日發佈了其財報。這家生物技術公司報告本季度每股收益為 ($1.20)，超出分析師共識預期的 ($1.38) $0.18。該公司本季度的收入為$29.73 百萬，而共識預期為$24.41 百萬。REGENXBIO 的股本回報率為-78.29%，淨利潤率為-110.29%。平均而言，研究分析師預測 REGENXBIO Inc.在當前財政年度將發佈-4.84 的每股收益。</p>
</div><h2>REGENXBIO Company Profile</h2>
<div class="lb-trans"><h2>REGENXBIO 公司簡介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>(獲取免費報告)</p>
</div><p>REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.</p>
<div class="lb-trans"><p>REGENXBIO Inc 是一家臨牀階段的生物技術公司，提供基因療法，將功能基因傳遞給美國的遺傳缺陷細胞。其基因療法產品候選者基於 NAV 技術平台，這是一種專有的腺病毒相關病毒基因傳遞平台。該公司的產品管線包括用於治療濕性年齡相關性黃斑變性、糖尿病視網膜病變和其他慢性視網膜疾病的 ABBV-RGX-314，以及正在進行 I/II 期臨牀試驗的 RGX-202，用於治療杜氏肌營養不良症。</p>
</div><h2>Featured Articles</h2>
<div class="lb-trans"><h2>精選文章</h2>
</div><ul>
<li>Five stocks we like better than REGENXBIO</li>
<li>Investing in Travel Stocks Benefits</li>
<li>Missed the AI Boom? These 2 Crushed Stocks Could Be Your Second Chance</li>
<li>What does consumer price index measure?</li>
<li>A New Leader at Six Flags: Is the Roller Coaster Over?</li>
<li>Stock Trading Terms - Stock Terms Every Investor Needs to Know</li>
<li>3 Reasons Baidu Could Be the Dark Horse of Global AI</li>
</ul>
<div class="lb-trans"><ul>
<li>我們更喜歡的五隻股票超過 REGENXBIO</li>
<li>投資旅遊股票的好處</li>
<li>錯過了人工智能的繁榮？這兩隻被壓制的股票可能是你的第二次機會</li>
<li>消費者價格指數測量什麼？</li>
<li>六旗的新領導者：過山車結束了嗎？</li>
<li>股票交易術語 - 每個投資者需要了解的股票術語</li>
<li>百度可能成為全球人工智能的黑馬的三個理由</li>
</ul>
</div><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即時新聞提醒由敍述科學技術和 MarketBeat 的金融數據生成，以便為讀者提供最快的報道和公正的覆蓋。請將任何問題或意見發送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in REGENXBIO Right Now?</h2>
<div class="lb-trans"><h2>你現在應該投資$1,000 在 REGENXBIO 嗎？</h2>
</div><p>Before you consider REGENXBIO, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考慮 REGENXBIO 之前，你需要聽聽這個。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟蹤華爾街頂級評級和表現最佳的研究分析師及其向客户推薦的股票。MarketBeat 已經識別出五隻頂級分析師正在悄悄向客户推薦的股票，建議在更廣泛的市場注意到之前購買……而 REGENXBIO 並不在名單上。</p>
</div><p>While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>雖然 REGENXBIO 目前在分析師中獲得了適度買入評級，但頂級分析師認為這五隻股票更值得購買。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在這裏查看這五隻股票</p>
</div>

REGENXBIO（納斯達克代碼：RGNX）在分析師上調評級後股價上漲 10.7%